JPMorgan raised the firm’s price target on Neurocrine (NBIX) to $184 from $183 and keeps an Overweight rating on the shares after surveying 24 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback